Suppr超能文献

甲胎蛋白、维生素K缺乏或拮抗剂-II诱导蛋白、单独及联合检测的甲胎蛋白刀豆球蛋白A反应性组分用于早期检测非酒精性脂肪性肝病相关肝细胞癌:一项多中心分析

Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.

作者信息

Guan Ming-Cheng, Ouyang Wei, Liu Si-Yu, Sun Li-Yang, Chen Wei-Yue, Tong Xiang-Min, Zhu Hong, Yang Tian

机构信息

Department of Medical Oncology, the First Affiliated Hospital of Soochow University, Suzhou 215006, China.

Department of Laboratory, Zhejiang University Lishui Hospital, Lishui 323000, China.

出版信息

Hepatobiliary Pancreat Dis Int. 2022 Dec;21(6):559-568. doi: 10.1016/j.hbpd.2022.05.003. Epub 2022 May 17.

Abstract

BACKGROUND

Current surveillance strategies for hepatocellular carcinoma (HCC) among patients with nonalcoholic fatty liver disease (NAFLD) are insufficient. This study aimed to investigate the diagnostic performance of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II), lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and their combinations in HCC underlying NAFLD patients.

METHODS

Serologic AFP, AFP-L3, and PIVKA-II levels in NAFLD patients with and without HCC were measured. By receiver operating characteristic (ROC) analyses, the area under the curve (AUC), sensitivity, and specificity were obtained to evaluate the diagnostic accuracy of each biomarker and their combinations.

RESULTS

This study was conducted on 139 patients with NAFLD-HCC and 345 NAFLD controls. The elevation of these three biomarkers was observed in patients with NAFLD-HCC compared to those in NAFLD controls (all P < 0.001). When they were analyzed individually, PIVKA-II showed the best performance in diagnosing any-stage HCC with an AUC of 0.869, followed by AFP (0.763; vs. PIVKA-II, P < 0.001) and AFP-L3 (0.689; vs. PIVKA-II, P < 0.001). When they were analyzed in combination, AFP + PIVKA-II yielded the highest AUC (0.906), followed by AFP + PIVKA-II + AFP-L3 (0.904; vs. AFP + PIVKA-II, P = 0.086), PIVKA-II + AFP-L3 (0.881; vs. AFP + PIVKA-II, P < 0.001), and AFP + AFP-L3 (0.759; vs. AFP + PIVKA-II, P < 0.001). Similar findings were obtained in the subgroup with early-stage NAFLD-HCC, as well as the non-cirrhotic subgroup.

CONCLUSIONS

These data validated the better diagnostic ability of PIVKA-II than AFP or AFP-L3 alone for diagnosing any-stage HCC among patients with NAFLD, and the combination of AFP + PIVKA-II significantly improved the diagnostic accuracy of NAFLD-HCC.

摘要

背景

目前非酒精性脂肪性肝病(NAFLD)患者肝细胞癌(HCC)的监测策略并不充分。本研究旨在调查甲胎蛋白(AFP)、维生素K缺乏或拮抗剂-II诱导蛋白(PIVKA-II)、甲胎蛋白的刀豆凝集素反应性部分(AFP-L3)及其组合在NAFLD相关HCC患者中的诊断效能。

方法

检测有和没有HCC的NAFLD患者的血清AFP、AFP-L3和PIVKA-II水平。通过受试者工作特征(ROC)分析,获得曲线下面积(AUC)、敏感性和特异性,以评估每个生物标志物及其组合的诊断准确性。

结果

本研究纳入了139例NAFLD-HCC患者和345例NAFLD对照。与NAFLD对照相比,NAFLD-HCC患者中这三种生物标志物均升高(所有P<0.001)。单独分析时,PIVKA-II在诊断各期HCC方面表现最佳,AUC为0.869,其次是AFP(0.763;与PIVKA-II相比,P<0.001)和AFP-L3(0.689;与PIVKA-II相比,P<0.001)。联合分析时,AFP+PIVKA-II的AUC最高(0.906),其次是AFP+PIVKA-II+AFP-L3(0.904;与AFP+PIVKA-II相比,P=0.086)、PIVKA-II+AFP-L3(0.881;与AFP+PIVKA-II相比,P<0.001)和AFP+AFP-L3(0.759;与AFP+PIVKA-II相比,P<0.001)。在早期NAFLD-HCC亚组以及非肝硬化亚组中也获得了类似的结果。

结论

这些数据证实,对于诊断NAFLD患者的各期HCC,PIVKA-II的诊断能力优于单独的AFP或AFP-L3,且AFP+PIVKA-II的组合显著提高了NAFLD-HCC的诊断准确性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验